ASTRALS Misses Phase II ALS Endpoints
Novartis discontinued VHB937, also known as lifonebart, in amyotrophic lateral sclerosis after the 251-participant Phase II ASTRALS study missed its primary and secondary endpoints. The company-issued community update was published August 25, 2026 and…
